PRLD vs USB · rev $6.5M vs P/E 12, rev $28.66B
Prelude Therapeutics Inc (PRLD) versus U.S. Bancorp (USB) — a side-by-side from cached financials, not a winner call.
Prelude Therapeutics Inc (PRLD) is a biotechnology company listed on NASDAQ.
U.S. Bancorp (USB) is a banks - regional company listed on US.
Latest reported PRLD revenue for 2025-09-30 was $6.5M. Net income was -$83.0M. Revenue was up 116.7% from 2024-09-30 to 2025-09-30. PRLD currently screens at market cap $346.5M.
Latest reported USB revenue for 2025-12-31 was $28.66B. Net income was $7.57B. Revenue was up 4.4% from 2024-12-31 to 2025-12-31. USB currently screens at market cap $74.68B and trailing P/E 11.9.
PRLD currently screens at market cap $346.5M. USB currently screens at market cap $74.68B and trailing P/E 11.9.
Not investment advice. Open the PRLD and USB stock pages for the full models.
Not investment advice.